Ribavirin, a broad-spectrum antiviral medication, has been studied for its potential efficacy against SARS-CoV-2, the virus responsible for COVID-19. Known for its ability to inhibit viral RNA synthesis, ribavirin has shown varying degrees of effectiveness in the context of SARS-CoV-2. Research into ribavirin's use for treating COVID-19 often involves combining it with other antiviral agents to enhance therapeutic outcomes. Although some studies suggest it might reduce viral load and improve patient recovery, others highlight concerns regarding its side effects, such as hemolytic anemia. As a result, ribavirin SARS-CoV-2 treatments are typically evaluated within controlled clinical trials to determine optimal usage and safety profiles.